<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR32">
 <label>32.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Niesvizky</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Flinn</surname>
    <given-names>IW</given-names>
   </name>
   <name>
    <surname>Rifkin</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Gabrail</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Charu</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Clowney</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Essell</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Gaffar</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Warr</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Neuwirth</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Elliott</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Esseltine</surname>
    <given-names>DL</given-names>
   </name>
   <name>
    <surname>Niculescu</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Reeves</surname>
    <given-names>J</given-names>
   </name>
  </person-group>
  <article-title>Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens</article-title>
  <source>J Clin Oncol</source>
  <year>2015</year>
  <volume>33</volume>
  <fpage>3921</fpage>
  <lpage>3929</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2014.58.7618</pub-id>
  <pub-id pub-id-type="pmid">26056177</pub-id>
 </element-citation>
</ref>
